Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug GMP definition high priority for Sept. MRA joint sectoral agenda committee meeting.

This article was originally published in The Tan Sheet

Executive Summary

DRUG GMP DEFINITION TO BE ON MRA JOINT SECTORAL AGENDA as a top priority at the scheduled September meeting of the Joint Sectoral Committee established under the U.S.-European Union Mutual Recognition Agreement to assist in the implementation and monitoring of the agreement. As drafted, the MRA calls for a "tentative merging" of U.S. and European Commission "concepts to be revisited" regarding methods to be used in, and the facilities and controls to be used for, the manufacturing, processing, packing and/or holding of a drug product.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088530

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel